Top

19-04-2024 | Rituximab | Letter to the Editors

Clinical significance of rituximab-associated hypogammaglobulinemia in nephrotic syndrome: to treat or not to treat?

Author: Eugene Yu-hin Chan

Excerpt

To the editor, …

Zurowska A, Drozynska-Duklas M, Topaloglu R, Bouts A, Boyer O, Shenoy M, Vivarelli M (2023) Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr Nephrol 38:3035–3042CrossRefPubMedPubMedCentral

Chan EY-H, Wong S-W, Lai FF-Y, Ho T-W, Tong P-C, Lai W-M, Ma AL-T, Yap DY-H (2023) Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol 38:4001–4011. https://doi.org/10.1007/s00467-023-06025-6CrossRefPubMed

Chan EY-H, Ma AL-T, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37:927–931. https://doi.org/10.1007/s00467-021-05345-9CrossRefPubMed

Title: Clinical significance of rituximab-associated hypogammaglobulinemia in nephrotic syndrome: to treat or not to treat?
Author: Eugene Yu-hin Chan
Publication date: 19-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Rituximab
Rituximab
Nephrotic Syndrome
Published in: Pediatric Nephrology
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-024-06379-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical significance of rituximab-associated hypogammaglobulinemia in nephrotic syndrome: to treat or not to treat?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content